小牛血清去蛋白注射液联合奥扎格雷治疗老年脑梗死的临床研究
|
摘要
目的探讨小牛血清去蛋白注射液联合奥扎格雷治疗老年脑梗死的临床效果。方法将2016年6月至2017年6月某院收治的老年脑梗死患者136例,按随机数表法分为两组,各68例。对照组予奥扎格雷静脉滴注治疗;观察组在此基础上,予小牛血清去蛋白注射液静脉滴注。连续治疗14 d后,比较两组患者临床疗效、神经功能、血液流变学指标及不良反应情况。结果治疗14 d后,观察组总有效率95.59%,明显高于对照组80.88%,差异具有统计学意义(P<0.05);治疗后观察组NIHSS评分低于对照组,MMSE评分高于对照组,差异均有统计学意义(P<0.05);治疗后观察组全血黏度、血浆黏度、血小板聚集率明显低于对照组,差异有统计学意义(P<0.05);观察组不良反应率为5.88%,对照组为8.82%,两组比较,差异无统计学意义(P>0.05)。结论小牛血清去蛋白注射液联合奥扎格雷治疗老年脑梗死临床疗效及安全性好,能够明显降低老年患者神经功能损伤。
Objective To investigate the clinical effect of deproteinized calf blood serum injection combined with ozagrel in the treatment of senile cerebral infarction.Me thods 136 senile patients with cerebral infarction admitted in a hospital from June,2016 to June,2017 were selected and divided into two groups by random number table,with 68 cases in each group.The control group was given intravenous drip of ozagrel while the observation group was given intravenous drip of deproteinized calf blood serum injection and intravenous drip of ozagrel.After 14 days of treatment,the clinical efficacy,nerve function,hemorheology indexes and adverse reactions were compared between the two groups.Re s ults After 14 days of treatment,the total effective rate of the observation group(95.59%) was significantly higher than that of the control group(80.88%) and the difference showed statistical significance( P <0.05).After the treatment,the NIHSS score of the observation group was lower than that of the control group while the MMSE score of the observation group was higher than that of the control group.The difference showed statistical significance(P <0.05).After the treatment,the blood viscosity,plasma viscosity,platelet aggregation rate in the observation group were significantly lower than those in the control group and the difference showed statistical significance(P <0.05).The incidence rate of adverse effect of the observation group was 5.88% while the rate of the control group was 8.82%.There was no statistical difference between the two groups( P >0.05).Conclus ion Deproteinized calf blood serum injection combined with ozagrel in the treatment of senile cerebral infarction was effective and safe which could significantly decrease nerve function injury among senior patients.
Objective To investigate the clinical effect of deproteinized calf blood serum injection combined with ozagrel in the treatment of senile cerebral infarction.Me thods 136 senile patients with cerebral infarction admitted in a hospital from June,2016 to June,2017 were selected and divided into two groups by random number table,with 68 cases in each group.The control group was given intravenous drip of ozagrel while the observation group was given intravenous drip of deproteinized calf blood serum injection and intravenous drip of ozagrel.After 14 days of treatment,the clinical efficacy,nerve function,hemorheology indexes and adverse reactions were compared between the two groups.Re s ults After 14 days of treatment,the total effective rate of the observation group(95.59%) was significantly higher than that of the control group(80.88%) and the difference showed statistical significance( P <0.05).After the treatment,the NIHSS score of the observation group was lower than that of the control group while the MMSE score of the observation group was higher than that of the control group.The difference showed statistical significance(P <0.05).After the treatment,the blood viscosity,plasma viscosity,platelet aggregation rate in the observation group were significantly lower than those in the control group and the difference showed statistical significance(P <0.05).The incidence rate of adverse effect of the observation group was 5.88% while the rate of the control group was 8.82%.There was no statistical difference between the two groups( P >0.05).Conclus ion Deproteinized calf blood serum injection combined with ozagrel in the treatment of senile cerebral infarction was effective and safe which could significantly decrease nerve function injury among senior patients.
引文
[1]帕力达·克里木,李?,李红燕.进展性缺血性脑卒中危险因素分析[J].中西医结合心脑血管病杂志,2018,16(4):507-508.
[2]毛洪兵.奥扎格雷钠联合依达拉奉治疗缺血性脑卒中的疗效分析[J].中国基层医药,2018,25(1):109-112.
[3]张星,张永明,赵霞,等.小牛血去蛋白提取物联合高压氧对HICH患者神经功能恢复的影响[J].脑与神经疾病杂志,2018,26(2):105-109.
[4]全国第四届脑血管病学术会议.各类脑血管疾病诊断要点[J].中华神经学杂志,1996,19(6):379-380.
[5]林晓萍,陈爱玲,陈炯,等.不同时间窗实施高压氧治疗对急性脑梗死患者NIHSS、ADL评分的影响[J].中国现代医生,2013,51(3):4-6.
[6]闫丽敏,代鸣明,于航.颈内动脉支架置入术联合药物治疗对重度颈内动脉狭窄者脑血流灌注及认知功能的影响[J].中山大学学报(医学科学版),2018,39(1):107-112.
[7]冯锦丽,王卫.急性脑梗死患者循环mi R-124表达水平与脑梗死体积、神经功能缺损程度的关系及其诊断价值[J].卒中与神经疾病,2018,25(1):21-24,38.
[8]许翠玉,高利.急性脑梗死中西医结合分型与相关性实验室指标探析[J].中西医结合心脑血管病杂志,2018,16(1):108-110.
[9]余飞,钟莺.奥扎格雷钠持续微量泵入联合心理干预对脑梗死的治疗效果分析[J].中国生化药物杂志,2017,37(10):322-323.
[10]谷海燕,丁国娟,胡兴越.奥扎格雷注射剂联合长春西汀注射剂治疗脑卒中患者的临床研究[J].中国临床药理学杂志,2017,33(13):1177-1180.
[11]陈颖青,何超明.奥扎格雷钠联合去蛋白小牛血清治疗急性脑梗死疗效观察[J].中国热带医学,2014,14(4):498-500.
[12]尹航,于倩,戴维群.小牛血清去蛋白注射液临床应用分析[J].中国药物应用与检测,2017,14(6):364-366,373.
[2]毛洪兵.奥扎格雷钠联合依达拉奉治疗缺血性脑卒中的疗效分析[J].中国基层医药,2018,25(1):109-112.
[3]张星,张永明,赵霞,等.小牛血去蛋白提取物联合高压氧对HICH患者神经功能恢复的影响[J].脑与神经疾病杂志,2018,26(2):105-109.
[4]全国第四届脑血管病学术会议.各类脑血管疾病诊断要点[J].中华神经学杂志,1996,19(6):379-380.
[5]林晓萍,陈爱玲,陈炯,等.不同时间窗实施高压氧治疗对急性脑梗死患者NIHSS、ADL评分的影响[J].中国现代医生,2013,51(3):4-6.
[6]闫丽敏,代鸣明,于航.颈内动脉支架置入术联合药物治疗对重度颈内动脉狭窄者脑血流灌注及认知功能的影响[J].中山大学学报(医学科学版),2018,39(1):107-112.
[7]冯锦丽,王卫.急性脑梗死患者循环mi R-124表达水平与脑梗死体积、神经功能缺损程度的关系及其诊断价值[J].卒中与神经疾病,2018,25(1):21-24,38.
[8]许翠玉,高利.急性脑梗死中西医结合分型与相关性实验室指标探析[J].中西医结合心脑血管病杂志,2018,16(1):108-110.
[9]余飞,钟莺.奥扎格雷钠持续微量泵入联合心理干预对脑梗死的治疗效果分析[J].中国生化药物杂志,2017,37(10):322-323.
[10]谷海燕,丁国娟,胡兴越.奥扎格雷注射剂联合长春西汀注射剂治疗脑卒中患者的临床研究[J].中国临床药理学杂志,2017,33(13):1177-1180.
[11]陈颖青,何超明.奥扎格雷钠联合去蛋白小牛血清治疗急性脑梗死疗效观察[J].中国热带医学,2014,14(4):498-500.
[12]尹航,于倩,戴维群.小牛血清去蛋白注射液临床应用分析[J].中国药物应用与检测,2017,14(6):364-366,373.